RESUMO
Loss of dopaminergic neurons is primarily responsible for the onset and progression of Parkinson's disease (PD); thus, neuroprotective and/or neuroregenerative strategies remain critical to the treatment of this increasingly prevalent disease. Here we explore a novel approach to neurotrophic factor-based therapy by engineering zinc finger protein transcription factors (ZFP TFs) that activate the expression of the endogenous glial cell line-derived neurotrophic factor (GDNF) gene. We show that GDNF activation can be achieved with exquisite genome-wide specificity. Furthermore, in a rat model of PD, striatal delivery of an adeno-associated viral vector serotype 2 encoding the GDNF activator resulted in improvements in forelimb akinesia, sensorimotor neglect, and amphetamine-induced rotations caused by 6-hydroxydopamine (6-OHDA) lesion. Our results suggest that an engineered ZFP TF can drive sufficient GDNF expression in the brain to provide functional neuroprotection against 6-OHDA; therefore, targeted activation of the endogenous gene may provide a method for delivering appropriate levels of GDNF to PD patients.
Assuntos
Terapia Genética/métodos , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Doença de Parkinson/terapia , Engenharia de Proteínas/métodos , Anfetamina/administração & dosagem , Animais , Linhagem Celular , Modelos Animais de Doenças , Dopaminérgicos/administração & dosagem , Ensaio de Imunoadsorção Enzimática/métodos , Regulação da Expressão Gênica/efeitos dos fármacos , Vetores Genéticos/fisiologia , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/biossíntese , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/genética , Proteínas de Fluorescência Verde/genética , Haplorrinos , Humanos , Lentivirus/fisiologia , Camundongos , Análise em Microsséries/métodos , Atividade Motora/efeitos dos fármacos , Oxidopamina/toxicidade , Doença de Parkinson/complicações , Doença de Parkinson/etiologia , RNA Mensageiro/metabolismo , Ratos , Fatores de Tempo , Transfecção , Tirosina 3-Mono-Oxigenase/metabolismo , Dedos de Zinco/genéticaRESUMO
Among the strategies developed for drug delivery into the CNS, locally controlled drug release by the way of an implantable polymeric device has been developed in recent years. The first polymeric devices developed were macroscopic implants needing open surgery for implantation. Over the last few years, poly(lactide-co-glycolide) microspheres have been shown to be safe and promising for drug delivery into the brain. Poly(lactide-co-glycolide) is biodegradable and biocompatible with brain tissue. Due to their size, these microspheres can be easily implanted by stereotaxy in discrete, precise and functional areas of the brain without causing damage to the surrounding -tissue. Brain tumour treatments have been developed using this approach and clinical trials have been performed. Potential applications in neurodegenerative diseases have also been explored, particularly neurotrophic factor delivery and cell therapy.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Materiais Biocompatíveis/química , Encéfalo/cirurgia , Sistemas de Liberação de Medicamentos , Fluoruracila/administração & dosagem , Glioma/tratamento farmacológico , Microesferas , Poliglactina 910/química , Animais , Antimetabólitos Antineoplásicos/uso terapêutico , Encéfalo/fisiopatologia , Transplante de Células/métodos , Ensaios Clínicos como Assunto , Dopamina/administração & dosagem , Dopamina/uso terapêutico , Implantes de Medicamento , Fluoruracila/uso terapêutico , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/administração & dosagem , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/uso terapêutico , Glioma/fisiopatologia , Humanos , Fator de Crescimento Neural/administração & dosagem , Fator de Crescimento Neural/uso terapêutico , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/fisiopatologia , Doenças Neurodegenerativas/terapia , Técnicas EstereotáxicasRESUMO
Regenerative medicine for Parkinson's disease (PD) is expected to develop dramatically with the advancement of biotechnology as represented by induced pluripotent stem cells. Existing therapeutic strategy for PD consists of medication using L-DOPA, surgery such as deep brain stimulation and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestoration is strongly desired by regenerative medicine. This review article describes the historical development of regenerative medicine for PD, with a focus on fetal nigral cell transplantation and glial cell line-derived neurotrophic factor infusion. Subsequently, the current status of regenerative medicine for PD in terms of cell therapy and gene therapy are reviewed. In the end, the future direction to realize regenerative medicine for PD is discussed.
Assuntos
Doença de Parkinson/terapia , Medicina Regenerativa/métodos , Animais , Antiparkinsonianos/uso terapêutico , Terapia Baseada em Transplante de Células e Tecidos/métodos , Ensaios Clínicos como Assunto , Terapia Combinada , Neurônios Dopaminérgicos/efeitos dos fármacos , Neurônios Dopaminérgicos/fisiologia , Descoberta de Drogas , Células-Tronco Fetais/transplante , Terapia Genética/métodos , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/uso terapêutico , Humanos , Levodopa/uso terapêutico , Doença de Parkinson/fisiopatologia , Células-Tronco Pluripotentes/transplante , Substância Negra/citologiaRESUMO
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction that occurs secondary to loss of dopaminergic neurons in the nigrostriatal pathway. Current pharmacotherapies focus on the replacement of lost dopamine to alleviate disease symptoms. However, over time this method of therapy loses effectiveness due to the continued death of dopaminergic neurons. Alternative strategies for the treatment of PD are aimed at modifying the disease state through the preservation of remaining dopamine neurons or even the regeneration of dopamine innervation through the use of neurotrophic factors. Neurotrophic factors are specialized proteins that can promote neuronal development, maintain neuronal health and modulate neuronal function in the ventral midbrain, making them candidates for the treatment of PD. Preclinial studies indicate that members of the glial cell line-derived neurotrophic factor family of ligands are capable of preserving the degenerating dopamine neurons. These promising results moved neurotrophic factor therapy to clinical trials in PD patients. To date, neurotrophic factor therapy is proven to be safe and well-tolerated in humans, but conclusive evidence of efficacy in the clinic remains to be determined. This review will discuss the preclinical and clinical experiments of glial cell line-derived neurotrophic factor family ligands for the treatment of PD.
Assuntos
Terapia Genética/métodos , Terapia Genética/tendências , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/genética , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/uso terapêutico , Degeneração Neural/terapia , Doença de Parkinson/terapia , Animais , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/metabolismo , Humanos , Degeneração Neural/genética , Degeneração Neural/metabolismo , Doença de Parkinson/genética , Doença de Parkinson/metabolismoRESUMO
Given improvements in viral vector design, production and efficiency of transduction in the central nervous system (CNS), as well as increased knowledge of neuropathological mechanisms in neurological disorders, success in treating a CNS disorder with gene transfer seems inevitable. Several different vector systems have been studied extensively and the adeno-associated viral vector system has been utilized in most early stage clinical trials in neurological disorders. Other vector systems, such as lentivirus, adenovirus, and herpes simplex virus are also viable vector platforms that should fill significant clinical niches based on their specific characteristics. In addition to the choice of the appropriate vector, the proper choice of transgene for the appropriate strategy to treat a neurological disorder is also critical. The example of glial cell line-derived neurotrophic factor ligands to treat Parkinson's disease is used to illustrate the importance of the interface between interpretation of pre-clinical data and consideration of the natural history of the disorder. This interface dictates the proper design of clinical trials that are capable of testing whether the treatment is actually successful.
Assuntos
Terapia Genética/métodos , Doença de Parkinson/terapia , Ensaios Clínicos como Assunto , Vetores Genéticos , Fator Neurotrófico Derivado de Linhagem de Célula Glial/genética , Fatores Neurotróficos Derivados de Linhagem de Célula Glial/uso terapêutico , HumanosRESUMO
Huntington's disease (HD) is a fatal, genetic, neurological disorder resulting from a trinucleotide repeat expansion in the gene that encodes for the protein huntingtin. These excessive repeats confer a toxic gain of function on huntingtin, which leads to the degeneration of striatal and cortical neurons and a devastating motor, cognitive, and psychological disorder. Trophic factor administration has emerged as a compelling potential therapy for a variety of neurodegenerative disorders, including HD. We previously demonstrated that viral delivery of glial cell line-derived neurotrophic factor (GDNF) provides structural and functional neuroprotection in a rat neurotoxin model of HD. In this report we demonstrate that viral delivery of GDNF into the striatum of presymptomatic mice ameliorates behavioral deficits on the accelerating rotorod and hind limb clasping tests in transgenic HD mice. Behavioral neuroprotection was associated with anatomical preservation of the number and size of striatal neurons from cell death and cell atrophy. Additionally, GDNF-treated mice had a lower percentage of neurons containing mutant huntingtin-stained inclusion bodies, a hallmark of HD pathology. These data further support the concept that viral vector delivery of GDNF may be a viable treatment for patients suffering from HD.